ProSensa Holding N.V. (RNA) Enrolls 100th Patient to its Natural History Study of Duchenne Muscular Dystrophy
11/7/2013 9:23:49 AM
Leiden, The Netherlands, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced the successful enrollment of the 100th patient into the Natural History Study of Duchenne muscular dystrophy (DMD).
Help employers find you! Check out all the jobs and post your resume.
comments powered by